The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of selinexor (KPT-330), a novel oral selective inhibitor of nuclear export (SINE), on tumor suppressors and cell cycle proteins in prostate cancer cells and regression of castration-resistant patient-derived xenograft tumor growth.
 
Sankar N. Maity
Research Funding - Viamet Pharmaceuticals (Inst)
 
Guanglin Wu
No Relationships to Disclose
 
Jing-Fang Lu
No Relationships to Disclose
 
Anh Hoang
No Relationships to Disclose
 
Yosef Landesman
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Dilara McCauley
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Robert Carlson
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Tami Rashal
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Sharon Shacham
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Bradley McIntosh Broom
No Relationships to Disclose
 
Keith A. Baggerly
No Relationships to Disclose
 
Ana Aparicio
No Relationships to Disclose
 
Eleni Efstathiou
No Relationships to Disclose
 
John C. Araujo
No Relationships to Disclose
 
Christopher Logothetis
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Johnson & Johnson; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Johnson & Johnson; Novartis; Pfizer
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Johnson & Johnson; Novartis; Pfizer